Comparative Study of Ramosetron and Ondansetron for Prevention of Chemotherapy Induced Nausea and Vomiting In Head & Neck Cancers
Study of Ramosetron and Ondansetron for Prevention of Chemotherapy Induced Nausea and Vomiting
Keywords:
Ondansetron, Ramosetron, Cisplatin, Vomiting, DelayedAbstract
Objective: To compare efficacy of Ramosetron and Ondansetron in the prevention of acute & delayed nausea and vomiting associated with cisplatin chemotherapy. Methods: 60 patients were recruited in the study. Patients were randomly allocated to ramosetron(R) & ondansetron group (O). Patients were initially screened for eligibility between day 1 and day 7. Study visits included clinic visits on day 8, day 9 and day 14. Patient diaries were used to record emetic episodes and severity of nausea, which were recorded daily until day 12 starting from day 8. On 14th day the patient diary cards were collected back. Results: Complete Response Rate (CRR) during the first 24 hours (acute phase) was non significantly higher in the R group (86.66%) as compared to O group (76.66%) (p> 0.05). For the delayed phase (24-120 hr.) & overall phase (0-120hrs), the proportion of patients achieving CRR was significantly higher for R group (86.66% for both phases) as compared to O group (78.33%, 78%, respectively) (p < 0.10, p<0.05, respectively) . Complete Control (CC) rate was higher in O group (90%) in acute phase as compared to R group(86.66%) but in delayed & in overall phase CC rate was greater in R group (87.6%, 87.3%) as compared to O group (81.6%, 83.33%)(p>0.05). Conclusion: Ramosetron and Ondansetron are equally effective in the prevention of cisplatin induced nausea and vomiting in acute phase (0-24 hrs). Ramosetron came out to be significantly more effective antiemetic agent in the prevention of delayed phase (24-120 hrs) and overall phases of CINV(0-120 hrs). [Swapnil S NJIRM 2017; 8(1):1-7]
References
vomiting : the importance of acute antiemetic
control. The Oncologist. 2002; 8:187-98.
2. Coates A, Abraham S, Kaye SB. On the receiving
end; patients’ perceptions of the side-effects of
cancer chemotherapy. Eur J Clin Oncol.
1983;19:203.
3. Grunberg SM, Densen RR, Mavros P, Geling O,
Hansen M, Cruciani G et al. Incidence of
chemotherapy induced nausea & emesis after
modern antiemetics. Cancer. 2004;100: 2261-3.
4. Daum BB, Deuson RR, Mavros P, Hansen M,
Herrestedt J. Delayed Nausea & Vomiting
Continue to Reduce Patient’s Quality of Life after
Highly & Moderately Emetogenic Chemotherapy
Despite Antiemetic Treatment. Journal of Clinical
Oncology. 2006; 24:4472-8.5. Andrews PLR, Davis CJ, Bighanis DH, Honvthoin J,
Mashell L. The abdominal visceral innervation and
the emetic reflex, pathway and plasticity. Can J
Physiol Pharmacol. 1990: 68: 325-45.
6. Habib AS, Gan TJ. Evidence based management of
post operative nausea and vomiting: A review.
Can. J. Anesth. 2004;51: 326-41.
7. Berger M, Gray JA, Roth BL Gray R. The expanded
biology of serotonin. Annu. Rev. Med. 2009; 60:
355–66.
8. Jones AW, Helander A. Time course and
reproducibility of urinary excretion profiles of
ethanol, methanol, and the ratio of serotonin
metabolites after intravenous infusion of ethanol.
Alcohol Clin Exp Res. 1999 Dec;23(12):1921-6.
9. Janelsins MC, Tejani M, Kamen C, Peoples A,
Mustian KM, Morrow GR. Current
Pharmacotherapy for Chemotherapy-Induced
Nausea and Vomiting in Cancer Patients. Expert
opinion on pharmacotherapy. 2013;14(6):757-66.
10. Rabasseda X. Ramosetron, a 5-HT3 receptor
antagonist for the control of nausea and vomiting.
Drugs Today (Barc). 2002;38:75-89.
11. Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata
M. Pharmacological profile of ramosetron, a novel
therapeutic agent for IBS. Inflammopharmacology.
2007;15(1):5-9.
12. Cheirsilpa A, Sinthusake T, Songsakkaesorn A,
Viswaprasit S, Chulaka K, Changkuingdee N.
Comparison of ramosetron and granisetron for the
prevention of acute and delayed emesis in
cisplatin based chemotherapy: A randomized trial.
Jpn J Clin Oncol. 2005; 35:695-9.
13. Kim MS, Kim DW, Woo SH, Yon JH, Lee S. Effect of
ramosetron on shivering during spinal
anaesthesia. Korean J Anesthesiol. 2010; 58:256-9.
14. Colevas AD, Setser A. The NCI Common
Terminology Criteria for Adverse Events(CTCAE)
v3.0 is the New Standard for Oncology clinical
trials. Journal of Clinical Oncology. 2004; 22: 6098.
15. Percie DS, Rudd JA, Adfel CC, Andrews PLR.
Cisplatin induced emesis: Systematic review and
metaanalysis of the ferret model & the effects of
5HT3 receptor antagonists. Cancer chemother
Pharmacol. 2011; 67(3):667-86.
16. Kang YK, Park YH, Ryoo BY, Bang YJ, Cho KS, Shin
DB, et al. Ramosetron for the prevention of
cisplatin-induced acute emesis: a prospective
randomized comparison with granisetron. J Int
Med Res. 2002;30:220–9.
17. Akuzawa S, Ito H, Yamaguchi T. Comparative
study of [3H] ramosetron and [3H] granisetron
binding in the cloned human 5-
hydroxytryptamine3 receptors. Jpn J
Pharmacol. 1998;78:381-4.
18. Sanmukhani JJ, Pawar P, Mittal R. Ramosetron
hydrochloride for the prevention of cancer
chemotherapy induced nausea and vomiting: The
Indian experience. South Asian Journal of Cancer.
2014;3(2):132-7.
19. Jang G, Song HH, Park KU. A Phase II Study to
Evaluate the Efficacy of Ramosetron, Aprepitant,
and Dexamethasone in Preventing Cisplatin-
Induced Nausea and Vomiting in Chemotherapy-
Naïve Cancer Patients. Cancer Research and
Treatment : Official Journal of Korean Cancer
Association. 2013;45(3):172-7.
20. Ito H, Akuzawa S, Tsutsumi R, Kiso T, Kamato
T, Nishida A et al. Comparative study of the
affinities of the 5-HT3 receptor antagonists,
YM060, YM114 (KAE-393), granisetron and
ondansetron in rat vagus nerve and cerebral
cortex. Neuropharmacology. 1995 Jun;34(6):631-
7.
21. Carlotto A, Hogsett VL, Maiorini EM. The
economic burden of toxicities associated with
cancer treatment: review of the literature and
analysis of nausea and vomiting, diarrhoea, oral
mucositis and fatigue. Pharmacoeconomics. 2013;
31 (9): 753-66.
